Company intelligence / Profile preview

QV Bioelectronics

Macclesfield / Alderley Park / Cheshire area, England, United Kingdomqvbio.co.uk ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Recent preclinical studies have demonstrated that the GRACE implant’s proprietary stimulation methodology outperforms the current industry leader in effectiveness against advanced patient-derived models of glioblastoma. Large animal studies have shown safety up to three months post implantation. The company has received positive feedback from FDA pre-submission, de-risking its path to first-in-human trials.

Therapeutic areas: OncologyNeurology
Modalities: DeviceNon-pharmacological therapy (Electric field therapy)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

GRACE

Pre-clinical

Indications: Glioblastoma

Beyond the preview

Go deeper on QV Bioelectronics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QV Bioelectronics.

Explore the full profile